About Pfenex (NYSEAMERICAN:PFNX)
Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: N/A
- Symbol: NYSEAMERICAN:PFNX
- Previous Symbol: NYSEMKT:PFNX
- CUSIP: N/A
- Web: www.pfenex.com
- Trailing EPS: ($1.78)
- Net Margins: -175.52%
- Return on Equity: -63.57%
- Return on Assets: -46.31%
- Outstanding Shares: 23,550,000
Frequently Asked Questions for Pfenex (NYSEAMERICAN:PFNX)
What is Pfenex's stock symbol?
Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."
How were Pfenex's earnings last quarter?
Pfenex Inc. (NYSEAMERICAN:PFNX) issued its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.17. The biotechnology company earned $5.02 million during the quarter, compared to the consensus estimate of $3.30 million. Pfenex had a negative net margin of 175.52% and a negative return on equity of 63.57%. The company's quarterly revenue was down 89.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.46 earnings per share. View Pfenex's Earnings History.
When will Pfenex make its next earnings announcement?
Where is Pfenex's stock going? Where will Pfenex's stock price be in 2017?
1 Wall Street analysts have issued 12 month price targets for Pfenex's stock. Their forecasts range from $8.00 to $8.00. On average, they expect Pfenex's stock price to reach $8.00 in the next twelve months. View Analyst Ratings for Pfenex.
Who are some of Pfenex's key competitors?
Some companies that are related to Pfenex include OncoCyte Corp (OCX), Verastem (VSTM), Conatus Pharmaceuticals (CNAT), ImmuPharma PLC (IMM), ProNAi Therapeutics (SRRA), MaxCyte (MXCT), Ophthotech Corporation (OPHT), Aldeyra Therapeutics (ALDX), Summit Therapeutics PLC (SUMM), Opexa Therapeutics (ACER), Axsome Therapeutics (AXSM), Redhill Biopharma (RDHL), Trevena (TRVN), Galmed Pharmaceuticals (GLMD), AcelRx Pharmaceuticals (ACRX), Verona Pharma Plc (VRP), Zafgen (ZFGN) and Gemphire Therapeutics (GEMP).
Who are Pfenex's key executives?
Pfenex's management team includes the folowing people:
- Evert B. Schimmelpennink, President, Chief Executive Officer, Acting Principal Financial Officer, Secretary, Director (Age 45)
- Patricia Lady CPA, Chief Accounting Officer (Age 58)
- Hubert C. Chen M.D., Chief Medical Officer (Age 48)
- Patrick K. Lucy, Chief Business Officer (Age 49)
- Robin D. Campbell Ph.D., Independent Director (Age 62)
- Dennis M. Fenton Ph.D., Independent Director (Age 65)
- Phillip M. Schneider, Independent Director (Age 60)
- John M. Taylor III, Independent Director (Age 52)
Who owns Pfenex stock?
Pfenex's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sanders Morris Harris LLC (4.24%), Dimensional Fund Advisors LP (1.29%), C WorldWide Group Holding A S (1.15%) and OxFORD Asset Management LLP (0.69%). Company insiders that own Pfenex stock include Bertrand C Liang, Chemical Co /De/ Dow, Henry W Jr Talbot, Jason Grenfell-Gardner, Patricia Lady, Patrick K Lucy and Signet Healthcare Partners Acc. View Institutional Ownership Trends for Pfenex.
Who sold Pfenex stock? Who is selling Pfenex stock?
Pfenex's stock was sold by a variety of institutional investors in the last quarter, including OxFORD Asset Management LLP. Company insiders that have sold Pfenex company stock in the last year include Patricia Lady and Signet Healthcare Partners Acc. View Insider Buying and Selling for Pfenex.
Who bought Pfenex stock? Who is buying Pfenex stock?
Pfenex's stock was purchased by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Dimensional Fund Advisors LP and C WorldWide Group Holding A S. View Insider Buying and Selling for Pfenex.
How do I buy Pfenex stock?
Shares of Pfenex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pfenex's stock price today?
One share of Pfenex stock can currently be purchased for approximately $2.81.
How big of a company is Pfenex?
Pfenex has a market capitalization of $66.88 million.
How can I contact Pfenex?
Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.
MarketBeat Community Rating for Pfenex (NYSEAMERICAN PFNX)MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Pfenex (NYSEAMERICAN:PFNX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$8.00|
Consensus Price Target History for Pfenex (NYSEAMERICAN:PFNX)
Analysts' Ratings History for Pfenex (NYSEAMERICAN:PFNX)
(Data available from 11/20/2015 forward)
|11/10/2017||JMP Securities||Lower Price Target||Positive -> Outperform||$21.00 -> $8.00|
|9/8/2017||William Blair||Reiterated Rating||Ourperform|
|8/9/2016||Mizuho||Lower Price Target||Buy||$22.00 -> $18.00|
|5/24/2016||Barclays PLC||Lower Price Target||Overweight||$28.00 -> $14.00|
Earnings History and Estimates Chart for Pfenex (NYSEAMERICAN:PFNX)
Earnings History by Quarter for Pfenex (NYSEAMERICAN PFNX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/21/2018|| || || || || || || || |
|11/9/2017||Q3 2017||($0.54)||($0.37)||$3.30 million||$5.02 million||View||N/A|
|8/9/2017||Q2 2017||($0.46)||($0.52)||$3.10 million||$3.03 million||View||Listen|
|5/8/2017||Q1 2017||($0.57)||($0.43)||$2.50 million||$2.80 million||View||Listen|
|3/15/2017||Q4 2016||($0.66)||($0.45)||$2.50 million||$5.47 million||View||N/A|
|11/9/2016||Q316||($0.56)||$1.46||$3.18 million||$48.82 million||View||Listen|
|8/8/2016||Q216||($0.47)||($0.43)||$2.55 million||$3.10 million||View||N/A|
|5/9/2016||Q116||($0.45)||($0.35)||$2.35 million||$2.76 million||View||N/A|
|3/10/2016||Q415||($0.59)||($0.37)||$2.56 million||$3.30 million||View||Listen|
|11/13/2015||Q315||($0.46)||($0.33)||$2.05 million||$2.06 million||View||Listen|
|8/13/2015||Q215||($0.39)||($0.27)||$2.07 million||$2.30 million||View||Listen|
|5/14/2015||Q115||($0.24)||($0.29)||$2.10 million||$2.00 million||View||Listen|
|3/16/2015||Q4||($0.20)||($0.18)||$2.05 million||$2.02 million||View||N/A|
|11/13/2014||Q3||($0.25)||($0.16)||$2.13 million||$2.80 million||View||N/A|
|8/29/2014||($0.15)||($1.67)||$1.75 million||$3.27 million||View||N/A|
Earnings Estimates for Pfenex (NYSEAMERICAN:PFNX)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Pfenex (NYSEAMERICAN:PFNX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Pfenex (NYSEAMERICAN PFNX)
Insider Trades by Quarter for Pfenex (NYSEAMERICAN PFNX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/12/2017||Jason Grenfell-Gardner||Director||Buy||10,000||$4.51||$45,100.00|| |
|5/16/2017||Patricia Lady||Insider||Sell||2,000||$4.78||$9,560.00|| |
|1/6/2017||Signet Healthcare Partners Acc||Major Shareholder||Sell||400||$9.50||$3,800.00|| |
|1/5/2017||Signet Healthcare Partners Acc||Major Shareholder||Sell||7,710||$9.50||$73,245.00|| |
|12/29/2016||Signet Healthcare Partners Acc||Major Shareholder||Sell||24,104||$9.66||$232,844.64|| |
|12/27/2016||Signet Healthcare Partners Acc||Major Shareholder||Sell||104,600||$9.58||$1,002,068.00|| |
|12/22/2016||Signet Healthcare Partners Acc||Major Shareholder||Sell||10,896||$9.61||$104,710.56|| |
|11/21/2016||Patricia Lady||Insider||Sell||2,000||$9.87||$19,740.00|| |
|11/15/2016||Patrick K. Lucy||Insider||Sell||5,000||$10.04||$50,200.00|| |
|8/18/2016||Patricia Lady||Insider||Sell||2,000||$9.42||$18,840.00|| |
|5/24/2016||Patricia Lady||CAO||Sell||2,000||$6.52||$13,040.00|| |
|5/24/2016||Patricia Lady||CAO||Sell||2,000||$6.52||$13,040.00|| |
|12/15/2015||Chemical Co /De/ Dow||Major Shareholder||Sell||600,000||$11.75||$7,050,000.00|| |
|12/3/2015||Patrick K Lucy||Insider||Sell||1,500||$14.15||$21,225.00|| |
|12/1/2015||Bertrand C. Liang||CEO||Sell||5,000||$14.88||$74,400.00|| |
|12/1/2015||Henry W Jr. Talbot||VP||Sell||2,000||$15.08||$30,160.00|| |
|11/18/2015||Patricia Lady||CAO||Sell||2,000||$14.05||$28,100.00|| |
|11/4/2015||Patrick K. Lucy||insider||Sell||1,500||$17.54||$26,310.00|| |
|11/2/2015||Bertrand C Liang||CEO||Sell||5,000||$18.01||$90,050.00|| |
|10/2/2015||Patrick K Lucy||Insider||Sell||1,500||$14.98||$22,470.00|| |
|10/1/2015||Bertrand C Liang||CEO||Sell||5,000||$14.78||$73,900.00|| |
|9/3/2015||Patricia Lady||CAO||Sell||2,000||$20.48||$40,960.00|| |
|9/3/2015||Patrick K Lucy||Insider||Sell||1,500||$20.91||$31,365.00|| |
|9/1/2015||Bertrand C. Liang||CEO||Sell||5,000||$21.02||$105,100.00|| |
|7/6/2015||Patrick K Lucy||Insider||Sell||1,500||$19.17||$28,755.00|| |
|7/1/2015||Bertrand C Liang||CEO||Sell||5,000||$19.63||$98,150.00|| |
|6/3/2015||Patrick K Lucy||Insider||Sell||1,500||$20.08||$30,120.00|| |
|6/1/2015||Bertrand C Liang||CEO||Sell||5,000||$18.70||$93,500.00|| |
|5/4/2015||Patrick K Lucy||Insider||Sell||1,500||$13.25||$19,875.00|| |
|5/1/2015||Bertrand C Liang||CEO||Sell||5,000||$13.49||$67,450.00|| |
|4/29/2015||Chemical Co /De/ Dow||Major Shareholder||Sell||2,232,233||$14.57||$32,523,634.81|| |
|4/29/2015||James C Gale||Director||Sell||1,907,767||$14.57||$27,796,165.19|| |
|4/2/2015||Patrick K Lucy||Insider||Sell||1,500||$17.62||$26,430.00|| |
|4/1/2015||Bertrand C Liang||CEO||Sell||5,000||$15.27||$76,350.00|| |
|3/4/2015||Patrick K Lucy||Insider||Sell||1,500||$14.36||$21,540.00|| |
|7/29/2014||Signet Healthcare Partners Acc||Major Shareholder||Sell||380,867||$0.31||$118,068.77|| |
Latest Headlines for Pfenex (NYSEAMERICAN PFNX)
Pfenex (NYSEAMERICAN PFNX) Chart for Monday, November, 20, 2017